Return On Capital Employed Overview: Surgery Partners

Looking at Q4, Surgery Partners SGRY earned $91.70 million, a 469.57% increase from the preceding quarter. Surgery Partners also posted a total of $548.30 million in sales, a 10.52% increase since Q3. Surgery Partners earned $16.10 million, and sales totaled $496.10 million in Q3.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Surgery Partners posted an ROCE of 0.06%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Surgery Partners's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q4 Earnings Insight

Surgery Partners reported Q4 earnings per share at $0.09/share, which beat analyst predictions of $0.02/share.